Study Protocol: Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Metastases

Manuela Robella, Paola Berchialla, Alice Borsano, Armando Cinquegrana, Alba Ilari Civit, Michele De Simone, Marco Vaira, Manuela Robella, Paola Berchialla, Alice Borsano, Armando Cinquegrana, Alba Ilari Civit, Michele De Simone, Marco Vaira

Abstract

Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) is a novel laparoscopic intraperitoneal chemotherapy approach offered in selected patients affected by non-resectable peritoneal carcinomatosis. Drugs doses currently established for nebulization are very low: oxaliplatin (OXA) 120 mg/sm, cisplatin (CDDP) 10.5 mg/sm and doxorubicin (DXR) 2.1 mg/sm. A model-based approach for dose-escalation design in a single PIPAC procedure and subsequent dose escalation steps is planned. The starting dose of oxaliplatin is 100 mg/sm with a maximum estimated dose of 300 mg/sm; an escalation with overdose and under-dose control (for probability of toxicity less than 16% in case of under-dosing and probability of toxicity greater than 33% in case of overdosing) will be further applied. Cisplatin is used in association with doxorubicin: A two-dimensional dose-finding design is applied on the basis of the estimated dose limiting toxicity (DLT) at all combinations. The starting doses are 15 mg/sm for cisplatin and 3 mg/sm for doxorubicin. Safety is assessed according to Common Terminology Criteria for Adverse Events (CTCAE version 4.03). Secondary endpoints include radiological response according to Response Evaluation Criteria in Solid Tumor (version 1.1) and pharmacokinetic analyses. This phase I study can provide the scientific basis to maximize the optimal dose of cisplatin, doxorubicin and oxaliplatin applied as PIPAC.

Trial registration: ClinicalTrials.gov NCT02604784.

Keywords: PIPAC; cisplatin; dose escalation; doxorubicin; oxaliplatin; peritoneal carcinomatosis; phase I.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic of single-port PIPAC set-up. The nebulizer connected to a standard injector and a laparoscope are inserted through a Quadport+ platform.

References

    1. Elias D., Lefevre J.H., Chevalier J., Brouquet A., Marchal F., Classe J.-M., Ferron G., Guilloit J.-M., Meeus P., Goéré D., et al. Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. J. Clin. Oncol. 2009;27:681–685. doi: 10.1200/JCO.2008.19.7160.
    1. Shirao K., Boku N., Yamada Y., Yamaguchi K., Doi T., Goto M., Nasu J., Denda T., Hamamoto Y., Takashima A., et al. Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106) Jpn. J. Clin. Oncol. 2013;43:972–980. doi: 10.1093/jjco/hyt114.
    1. Thomassen I., Van Gestel Y.R., Van Ramshorst B., Luyer M.D., Bosscha K., Nienhuijs S.W., Lemmens V.E., De Hingh I.H. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int. J. Cancer. 2014;134:622–628. doi: 10.1002/ijc.28373.
    1. Hanker L.C., Loibl S., Burchardi N., Pfisterer J., Meier W., Pujade-Lauraine E., Ray-Coquard I., Sehouli J., Harter P., du Bois A. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann. Oncol. 2012;23:2605–2612. doi: 10.1093/annonc/mds203.
    1. Ceelen W.P., Flessner M.F. Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence. Nat. Rev. Clin. Oncol. 2009;7:108–115. doi: 10.1038/nrclinonc.2009.217.
    1. Dedrick R.L., Flessner M.F. Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure. J. Natl. Cancer Inst. 1997;89:480–487. doi: 10.1093/jnci/89.7.480.
    1. Yamaguchi H., Kitayama J., Ishigami H., Kazama S., Nozawa H., Kawai K., Hata K., Kiyomatsu T., Tanaka T., Tanaka J., et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. World J. Gastrointest. Oncol. 2015;7:285–291. doi: 10.4251/wjgo.v7.i11.285.
    1. Wright A.A., Cronin A.M., Milne D.E., Bookman M.A., Burger R.A., Cohn D.E., Cristea M.C., Griggs J.J., Keating N.L., Levenback C.F., et al. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J. Clin. Oncol. 2015;33:2841–2847. doi: 10.1200/JCO.2015.61.4776.
    1. Hirose K., Katayama K., Iida A., Yamaguchi A., Nakagawara G., Umeda S.-I., Kusaka Y. Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis. Oncology. 1999;57:106–114. doi: 10.1159/000012016.
    1. Alkhamesi N.A., Ridgway P.F., Ramwell A., McCullough P.W., Peck D.H., Darzi A.W. Peritoneal nebulizer: A novel technique for delivering intraperitoneal therapeutics in laparoscopic surgery to prevent locoregional recurrence. Surg. Endosc. 2005;19:1142–1146. doi: 10.1007/s00464-004-2214-3.
    1. Jacquet P., Stuart O.A., Chang D., Sugarbaker P.H. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anti-Cancer Drugs. 1996;7:596–603. doi: 10.1097/00001813-199607000-00016.
    1. Esquis P., Consolo D., Magnin G., Pointaire P., Moretto P., Ynsa M.D., Beltramo J.-L., Drogoul C., Simonet M., Benoit L., et al. High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis. Ann. Surg. 2006;244:106–112. doi: 10.1097/01.sla.0000218089.61635.5f.
    1. Robella M., Vaira M., De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: An innovative approach to treat peritoneal carcinomatosis. World J. Surg. Oncol. 2016;14:128. doi: 10.1186/s12957-016-0892-7.
    1. Alyami M., Gagniere J., Sgarbura O., Cabelguenne D., Villeneuve L., Pezet D., Quenet F., Glehen O., Bakrin N., Passot G. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur. J. Surg. Oncol. (EJSO) 2017;43:2178–2183. doi: 10.1016/j.ejso.2017.09.010.
    1. Giger-Pabst U., Demtröder C., Falkenstein T.A., Ouaissi M., Götze T.O., Rezniczek G.A., Tempfer C.B. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer. 2018;18:442. doi: 10.1186/s12885-018-4363-0.
    1. Tempfer C.B., Giger-Pabst U., Seebacher V., Petersen M., Dogan A., Rezniczek G.A. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol. Oncol. 2018;150:23–30. doi: 10.1016/j.ygyno.2018.05.001.
    1. Kim G., Tan H.L., Sundar R., Lieske B., Chee C.E., Ho J., Shabbir A., Babak M.V., Ang W.H., Goh B.C., et al. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. Clin. Cancer Res. 2021;27:1875–1881. doi: 10.1158/1078-0432.CCR-20-2152.
    1. Tempfer C.B., Winnekendonk G., Solass W., Horvat R., Giger-Pabst U., Zieren J., Rezniczek G.A., Reymond M.-A. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol. Oncol. 2015;137:223–228. doi: 10.1016/j.ygyno.2015.02.009.
    1. De Simone M., Vaira M., Argenziano M., Berchialla P., Pisacane A., Cinquegrana A., Cavalli R., Borsano A., Robella M. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial. Biomedicines. 2020;8:102. doi: 10.3390/biomedicines8050102.
    1. Nadiradze G., Giger-Pabst U., Zieren J., Strumberg D., Solass W., Reymond M.-A. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis. J. Gastrointest. Surg. 2016;20:367–373. doi: 10.1007/s11605-015-2995-9.
    1. Alyami M., Hübner M., Grass F., Bakrin N., Villeneuve L., Laplace N., Passot G., Glehen O., Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368–e377. doi: 10.1016/S1470-2045(19)30318-3.
    1. Oyais A., Solass W., Zieren J., Reymond M., Giger-Pabst U. Occupational Health Aspects of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC): Confirmation of Harmlessness. Zentralbl. Chir. 2014;141:421–424. doi: 10.1055/s-0033-1350909.
    1. Odendahl K., Solass W., Demtröder C., Giger-Pabst U., Zieren J., Tempfer C., Reymond M. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Eur. J. Surg. Oncol. (EJSO) 2015;41:1379–1385. doi: 10.1016/j.ejso.2015.06.001.
    1. Vaira M., Robella M., Borsano A., De Simone M. Single-port access for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): Technique, feasibility and safety. Pleura Peritoneum. 2016;1:217–222. doi: 10.1515/pp-2016-0021.
    1. Riviere M.-K., Yuan Y., Dubois F., Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharm. Stat. 2014;13:247–257. doi: 10.1002/pst.1621.
    1. Neuenschwander B., Branson M., Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat. Med. 2008;27:2420–2439. doi: 10.1002/sim.3230.
    1. Thall P.F., Lee S.-J. Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity. Int. J. Gynecol. Cancer. 2003;13:251–261. doi: 10.1046/j.1525-1438.2003.13202.x.
    1. Prada-Villaverde A., Esquivel J., Lowy A.M., Markman M., Chua T., Pelz J., Baratti D., Baumgartner J.M., Berri R., Bretcha-Boix P., et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J. Surg. Oncol. 2014;110:779–785. doi: 10.1002/jso.23728.
    1. Struller F., Horvath P., Solass W., Weinreich F.-J., Strumberg D., Kokkalis M.K., Fischer I., Meisner C., Königsrainer A., Reymond M.A. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: A phase II study. Ther. Adv. Med Oncol. 2019;11:1758835919846402. doi: 10.1177/1758835919846402.
    1. Kim G., Tan H.L., Chen E., Teo S.C., Jang C.J.M., Ho J., Ang Y., Ngoi N.Y.L., Chee C.E., Lieske B., et al. Study protocol: Phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. Pleura Peritoneum. 2018;3:20180118. doi: 10.1515/pp-2018-0118.
    1. Dumont F., Senellart H., Pein F., Campion L., Glehen O., Goere D., Pocard M., Thibaudeau E. Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design. Pleura Peritoneum. 2018;3:20180120. doi: 10.1515/pp-2018-0120.
    1. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N. Engl. J. Med. 2006;354:34–43. doi: 10.1056/NEJMoa052985.
    1. Sugarbaker P., Van Der Speeten K., Stuart O.A., Chang D. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur. J. Surg. Oncol. (EJSO) 2011;37:719–726. doi: 10.1016/j.ejso.2011.04.007.
    1. Van Der Speeten K., Stuart O.A., Mahteme H., Sugarbaker P.H. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother. Pharmacol. 2009;63:799–805. doi: 10.1007/s00280-008-0800-0.
    1. Zivanovic O., Abramian A., Kullmann M., Fuhrmann C., Coch C., Hoeller T., Ruehs H., Keyver-Paik M.D., Rudlowski C., Weber S., et al. HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int. J. Cancer. 2014;136:699–708. doi: 10.1002/ijc.29011.
    1. Maindrault-Goebel F., De Gramont A., Louvet C., André T., Carola E., Gilles V., Lotz J.-P., Tournigand C., Mabro M., Molitor J.-L., et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann. Oncol. 2000;11:1477–1483. doi: 10.1023/A:1026520812351.
    1. Rossi C.R., Mocellin S., Pilati P., Foletto M., Quintieri L., Palatini P., Lise M. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg. Oncol. Clin. N. Am. 2003;12:781–794. doi: 10.1016/S1055-3207(03)00030-9.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere